Frontage Laboratories and Spaulding Clinical Research have entered into a strategic partnership to establish a global footprint, combining Frontage’s presence in China and expertise in drug formulation and bioanalytical analysis with Spaulding’s cardiac safety and fully-automated clinical pharmacology facility.

Spaulding Clinical will perform all intense electrocardiographic studies in its facility and provide ECG Core Lab services on behalf of Frontage. Frontage will provide bioanalytical method development and sample processing, formulation development and clinical trial product supplies for Spaulding, as well as serve as one of the clinical sites for Spaulding clients in China.

“Throughout the due diligence process, we were thoroughly impressed with the innovative, quality-focused clinical conduct we witnessed at Spaulding,” said Song Li, Ph.D., chief executive officer and chairman of Frontage Laboratories. “The collaboration with Spaulding Clinical will enable Frontage to better service our current and potential clients in a more comprehensive approach, especially in the areas of cardiac safety, thorough QT, and ECG Core Lab.”

Randy Spaulding, chief executive officer and founder of Spaulding Clinical, added, “This collaboration represents another step forward in meeting our strategic objectives of providing the highest quality global clinical development facilities to our clients interested in accelerating drug development. Together, Frontage and Spaulding Clinical will deliver the first US-based fully-automated Clinical Pharmacology unit in China.”